GSK 3196165

Drug Profile

GSK 3196165

Alternative Names: GSK-3196165; MOR-103

Latest Information Update: 20 May 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator MorphoSys
  • Developer GlaxoSmithKline; MorphoSys
  • Class Anti-inflammatories; Antirheumatics; Monoclonal antibodies
  • Mechanism of Action Granulocyte macrophage colony stimulating factor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Osteoarthritis; Rheumatoid arthritis
  • No development reported Inflammation
  • Discontinued Multiple sclerosis

Most Recent Events

  • 01 Jan 2017 Phase-I/II clinical trials in Rheumatoid arthritis (Combination therapy, Treatment-experienced) in Japan (SC) (NCT03028467)
  • 15 Dec 2016 Biomarkers information updated
  • 09 Jun 2016 GlaxoSmithKline plans a phase IIa trial for Rheumatoid arthritis (Combination therapy, Treatment-experienced) in USA, Germany and Poland (SC) (NCT02799472)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top